1. Gastrointestinal Endoscopy
Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial 
Reginald Bell, MD, John Lipham, MD, Brian Louie, MD, Valerie Williams, MD, James Luketich, MD, Michael Hill, MD, William Richards, MD, Christy Dunst, MD, Dan Lister, MD, Lauren McDowell-Jacobs, MD, Patrick Reardon, MD, Karen Woods, MD, Jon Gould, MD, F. Paul Buckley, MD, Shanu Kothari, MD, Leena Khaitan, MD, C. Daniel Smith, MD, Adrian Park, MD, Christopher Smith, MD, Garth Jacobsen, MD, Ghulam Abbas, MD, Philip Katz, MD 
Gastrointestinal Endoscopy 
DOI: /j.gie
Copyright © 2018 American Society for Gastrointestinal Endoscopy Terms and Conditions

2. Gastrointestinal Endoscopy DOI: (10.1016/j.gie.2018.07.007)
Copyright © 2018 American Society for Gastrointestinal Endoscopy Terms and Conditions

3. Figure 1
Study design and patient disposition. MSA, magnetic sphincter augmentation; BID, twice daily; PPI, proton pump inhibitor.
Gastrointestinal Endoscopy DOI: ( /j.gie )
Copyright © 2018 American Society for Gastrointestinal Endoscopy Terms and Conditions

4. Figure 2
Results at 6-month endpoint. A, Percentage of patients achieving relief from regurgitation. B, Percentage of patients achieving ≥ 50% improvement (decrease) in GERD–health-related quality of life scores from baseline score on once-daily proton pump inhibitor therapy. C, Percentage of patient satisfaction with current condition. HRQL, health-related quality of life; MSA, magnetic sphincter augmentation; BID, twice daily; PPI, proton pump inhibitor.
Gastrointestinal Endoscopy DOI: ( /j.gie )
Copyright © 2018 American Society for Gastrointestinal Endoscopy Terms and Conditions

5. Figure 3
Percentage of patients treated with magnetic sphincter augmentation or twice daily proton pump inhibitor therapy at the 6-month endpoint with no, mild, or moderate-to-severe regurgitation. MSA, magnetic sphincter augmentation; BID, twice daily; PPI, proton pump inhibitor.
Gastrointestinal Endoscopy DOI: ( /j.gie )
Copyright © 2018 American Society for Gastrointestinal Endoscopy Terms and Conditions

6. Figure 4
Results at 6-month endpoint. A, Percentage of patients with normal (<57) number of reflux episodes. B, Percentage of patients with normal DeMeester scores (<14.7). C, Percentage of patients with normal time with (<4.5%) pH <4. MSA, magnetic sphincter augmentation; BID, twice daily; PPI, proton pump inhibitor.
Gastrointestinal Endoscopy DOI: ( /j.gie )
Copyright © 2018 American Society for Gastrointestinal Endoscopy Terms and Conditions